1 week Ago By ABMN Staff
Versant Capital Management Inc raised its holdings in shares of Bristol-Myers Squibb ( NYSE:BMY – Free Report ) by 14.0% in the 4th quarter, Holdings Channel reports. The firm owned 78,690 shares of the biopharmaceutical company’s stock after purchasing an additional 9,692 shares during the quarter.
Bristol-Myers Squibb accounts for 1.0% of Versant Capital Management Inc’s holdings, making the stock its 21st biggest holding. Versant Capital Management Inc’s holdings in Bristol-Myers Squibb were worth $4,451,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in the stock. Reston Wealth Management LLC purchased a new stake in Bristol-Myers Squibb in the 3rd quarter valued at about $25,000. Hollencrest Capital Management boosted its holdings in shares of Bristol-Myers Squibb by 61.
3% in the third quarter. Hollencrest Capital Management now owns 492 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 187 shares during the period. Kennebec Savings Bank bought a new position in Bristol-Myers Squibb in the third quarter worth approximately $28,000.
Darwin Wealth Management LLC purchased a new position in Bristol-Myers Squibb during the 3rd quarter worth $29,000. Finally, Valued Wealth Advisors LLC lifted its holdings in shares of Bristol-Myers Squibb by 1,168.1% in the 3rd quarter.
Valued Wealth Advisors LLC now owns 596 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 549 shares during the period. 76.41% of the stock is currently owned by institutional investors.
Bristol-Myers Squibb Trading Up 0.4 % Shares of Bristol-Myers Squibb stock opened at $56.79 on Friday.
The firm’s 50 day simple moving average is $57.04 and its two-hundred day simple moving average is $50.79.
The firm has a market capitalization of $115.18 billion, a price-to-earnings ratio of -15.82, a PEG ratio of 15.
20 and a beta of 0.45. Bristol-Myers Squibb has a 12-month low of $39.
35 and a 12-month high of $61.08. The company has a current ratio of 1.
24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83.
Bristol-Myers Squibb Increases Dividend The business also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be given a dividend of $0.62 per share.
This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.
48 annualized dividend and a yield of 4.37%. The ex-dividend date is Friday, January 3rd.
Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -69.08%. Insider Buying and Selling at Bristol-Myers Squibb In other news, EVP Samit Hirawat bought 1,830 shares of the stock in a transaction dated Friday, November 1st.
The shares were acquired at an average cost of $54.67 per share, with a total value of $100,046.10.
Following the purchase, the executive vice president now directly owns 62,109 shares in the company, valued at $3,395,499.03. The trade was a 3.
04 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website . Also, SVP Phil M.
Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.
00. Following the completion of the transaction, the senior vice president now owns 11,760 shares of the company’s stock, valued at approximately $654,091.20.
This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here .
Company insiders own 0.09% of the company’s stock. Analyst Ratings Changes Several research firms recently weighed in on BMY.
Leerink Partnrs upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 12th. Bank of America restated a “neutral” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th.
Citigroup increased their price objective on shares of Bristol-Myers Squibb from $55.00 to $60.00 and gave the company a “neutral” rating in a research note on Tuesday, November 12th.
Wolfe Research began coverage on shares of Bristol-Myers Squibb in a research note on Friday, November 15th. They issued a “peer perform” rating for the company. Finally, Leerink Partners raised Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and increased their target price for the company from $55.
00 to $73.00 in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, three have given a buy rating and three have given a strong buy rating to the company’s stock.
According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $55.64.
Read Our Latest Analysis on Bristol-Myers Squibb About Bristol-Myers Squibb ( Free Report ) Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
See Also Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb ( NYSE:BMY – Free Report ). Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.
com's FREE daily email newsletter ..
